Objective: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy. CD8+ T
cells, cancer stem cells (CSCs), and tumor budding (TB) have been significantly correlated …

Pancreatic adenocarcinoma (PAAD) carries the lowest survival rate of all major organ
cancers, which is of dismal prognosis and high mortality rate. Thus, the present study …

Background Pancreatic ductal adenocarcinoma (PDAC) is one of the most invasive solid
malignancies. Immunotherapy and targeted therapy confirmed an existing certain curative …

Tumor-infiltrating immune cells and fibroblasts are significant components of the tumor
microenvironment (TME) of pancreatic ductal adenocarcinoma (PDAC), and they participate …

Background. The prognosis of pancreatic adenocarcinoma (PAAD) is extremely poor and
has not been improved. Thus, an effective method to assess the prognosis of patients must …

Objective Tumor-infiltrating immune cells might add a predictive value for the prognostic
stratification of patients with pancreatic ductal adenocarcinoma (PDAC) and chemotherapy …

Objectives This study constructed and validated a machine learning model to predict CD8+
tumor-infiltrating lymphocyte expression levels in patients with pancreatic ductal …

Pancreatic cancer (PC) is a highly lethal and aggressive disease with its incidence and
mortality quite discouraging. A robust prognostic signature and novel biomarkers are …

The abundance of cytotoxic T-cell infiltrates has important implications for patient outcome
and therapeutic design for pancreatic ductal adenocarcinoma. However, intratumoral …

Purpose The current clinical classification of pancreatic ductal adenocarcinoma (PDAC)
cannot well predict the patient's possible response to the treatment plan, nor can it predict …